Clinical results of the EVESOR trial, a multiparameter phase I trial of everolimus and sorafenib combination in solid tumors Romain VarnierAlicja PuszkielBenoit You Original Article 25 February 2023 Pages: 361 - 373
Synergistic action of lactoferrin in enhancing the safety and effectiveness of docetaxel treatment against prostate cancer Chukhu MujSatyajit MukhopadhyayAnand K. Kondapi Original Article 29 March 2023 Pages: 375 - 387
Cardioprotective potential of mitochondria-targeted antioxidant, mito-TEMPO, in 5-fluorouracil-induced cardiotoxicity Prasad Kisan TambeA. Jesil MathewSanjay Bharati Original Article Open access 30 March 2023 Pages: 389 - 400
The novel anti-cancer fluoropyrimidine NUC-3373 is a potent inhibitor of thymidylate synthase and an effective DNA-damaging agent Jennifer BréAlison L. DicksonDavid J. Harrison Original Article Open access 31 March 2023 Pages: 401 - 412
A PK-PD model linking biomarker dynamics to progression-free survival in patients treated with everolimus and sorafenib combination therapy, EVESOR phase I trial Alicja PuszkielBenoit YouMichel Tod Original Article 03 April 2023 Pages: 413 - 425
Plasma endothelin-1 may predict bevacizumab-induced proteinuria in patients with colorectal cancer Satoru NiheiTatsuki IkedaKenzo Kudo Original Article 10 April 2023 Pages: 427 - 434
Precision fluoropyrimidines dosing in a compound heterozygous variant carrier of the DPYD gene: a case report Giammarco BaiardiMatteo ClavarezzaFrancesca Mattioli Short Communication 08 March 2023 Pages: 435 - 439
A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia Pau MontesinosVamsi KotaMary Frances McMullin Short Communication Open access 09 March 2023 Pages: 441 - 446